These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37740457)

  • 1. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data.
    Fishman J; Tapper EB; Dodge S; Miller K; Lewandowski D; Bogdanov A; Bonafede M
    Curr Med Res Opin; 2023 Nov; 39(11):1425-1429. PubMed ID: 37740457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
    Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
    J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
    McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
    J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
    Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
    Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
    Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
    Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
    Fishman J; Kim Y; Parisé H; Bercaw E; Smith Z
    J Med Econ; 2024; 27(1):1108-1118. PubMed ID: 39155764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
    Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
    J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
    Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis: Danish nationwide register-based study.
    Rudolfsen JH; Gluud LL; Grønbæk H; Jensen MK; Vyberg M; Olsen J; Bo Poulsen P; Hovelsø N; Gregersen NT; Thomsen AB; Jepsen P
    Ann Hepatol; 2024; 29(3):101285. PubMed ID: 38272183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.
    Waddell T; Namburete A; Duckworth P; Fichera A; Telford A; Thomaides-Brears H; Cuthbertson DJ; Brady M
    Front Endocrinol (Lausanne); 2023; 14():1063882. PubMed ID: 36909341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
    O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
    JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
    Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
    Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
    Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
    Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes.
    Lauren BN; Lim F; Krikhely A; Taveras EM; Woo Baidal JA; Bellows BK; Hur C
    JAMA Netw Open; 2022 Feb; 5(2):e2148317. PubMed ID: 35157054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.